Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Brookdale Senior Living (BKD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND), Brookdale Senior Living (BKD) and United Therapeutics (UTHR) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ligand Pharma (LGND)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma, with a price target of $289.00. The company’s shares closed last Thursday at $214.28.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Ligand Pharma has an analyst consensus of Strong Buy, with a price target consensus of $277.86, implying a 35.5% upside from current levels. In a report issued on April 23, TipRanks – Google also upgraded the stock to Buy with a $252.00 price target.
See the top stocks recommended by analysts >>
Brookdale Senior Living (BKD)
In a report released today, Brian Tanquilut from Jefferies maintained a Buy rating on Brookdale Senior Living, with a price target of $23.00. The company’s shares closed last Thursday at $13.57.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Brookdale Senior Living with a $19.10 average price target, a 44.4% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $18.00 price target.
United Therapeutics (UTHR)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on United Therapeutics, with a price target of $660.00. The company’s shares closed last Thursday at $575.74.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $648.00 average price target, representing an 8.2% upside. In a report released today, Wells Fargo also upgraded the stock to Buy with a $738.00 price target.
Read More on LGND:
